RhumbLine Advisers’s Ariad Pharmaceuticals Inc ARIA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-206,352
| Closed | -$2.57M | – | 2869 |
|
|
2016
Q4 | $2.57M | Buy |
206,352
+13,614
| +7% | +$164K | 0.01% | 1303 |
|
|
2016
Q3 | $2.64M | Buy |
192,738
+4,175
| +2% | +$41.9K | 0.01% | 1235 |
|
|
2016
Q2 | $1.39M | Buy |
188,563
+14,675
| +8% | +$110K | ﹤0.01% | 1585 |
|
|
2016
Q1 | $1.11M | Sell |
173,888
-305
| -0.2% | -$1.71K | ﹤0.01% | 1725 |
|
|
2015
Q4 | $1.09M | Buy |
174,193
+12,560
| +8% | +$82.4K | ﹤0.01% | 1749 |
|
|
2015
Q3 | $944K | Buy |
161,633
+2,995
| +2% | +$23.1K | ﹤0.01% | 1799 |
|
|
2015
Q2 | $1.31M | Sell |
158,638
-4,625
| -3% | -$40.9K | ﹤0.01% | 1692 |
|
|
2015
Q1 | $1.34M | Buy |
163,263
+26,075
| +19% | +$193K | ﹤0.01% | 1675 |
|
|
2014
Q4 | $942K | Sell |
137,188
-5,218
| -4% | -$32.6K | ﹤0.01% | 1855 |
|
|
2014
Q3 | $769K | Buy |
142,406
+420
| +0.3% | +$2.45K | ﹤0.01% | 1929 |
|
|
2014
Q2 | $904K | Sell |
141,986
-1,526
| -1% | -$10.5K | ﹤0.01% | 1895 |
|
|
2014
Q1 | $1.16M | Sell |
143,512
-7,237
| -5% | -$56.4K | ﹤0.01% | 1699 |
|
|
2013
Q4 | $1.03M | Sell |
150,749
-16,873
| -10% | -$91.1K | ﹤0.01% | 1788 |
|
|
2013
Q3 | $3.08M | Sell |
167,622
-3,748
| -2% | -$72.8K | 0.01% | 1074 |
|
|
2013
Q2 | $3M | Buy |
+171,370
| New | +$3.04M | 0.01% | 1063 |
|
Other funds holding ARIA
RhumbLine Advisers's ARIA Position: Q1 2017 in Review
RhumbLine Advisers sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 206,352 shares — an estimated $2.57M sold.
RhumbLine Advisers first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $3.08M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.
- RhumbLine Advisers reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
- RhumbLine Advisers sold 206,352 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $2.57M.
- RhumbLine Advisers first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
- RhumbLine Advisers's Ariad Pharmaceuticals Inc position peaked at $3.08M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.